|
Treatment
|
Dosage (μg/ml)
|
Infected cells (%)
|
Viability of amastigotes (%)
|
Parasite load
|
Survival index
|
|---|
|
Control
|
0
|
85.37 ± 3.58
|
100 ± 0.00
|
3.19 ± 0.01
|
270.9 ± 1.15
|
|
Crude ES
|
150
|
41.66 ± 1.28*
|
30.27 ± 1.93*
|
1.97 ± 0.02*
|
82.23 ± 2.35*
|
| |
300
|
32.00 ± 2.43*
|
20.58 ± 2.74*
|
1.75 ± 0.05*
|
53.72 ± 2.44*
|
|
> 10-kDa ES
|
150
|
58.33 ± 2.75
|
49.90 ± 2.71*
|
2.28 ± 0.03
|
132.99 ± 2.01*
|
| |
300
|
51.00 ± 1.55*
|
39.46 ± 3.42*
|
2.10 ± 0.01*
|
107.33 ± 2.51*
|
|
< 10-kDa ES
|
150
|
62.66 ± 2.38
|
59.93 ± 2.86*
|
2.60 ± 0.10
|
162.73 ± 2.10*
|
| |
300
|
55.00 ± 3.10*
|
49.02 ± 3.53*
|
2.42 ± 0.00*
|
133.21 ± 2.38*
|
|
Glucantime
|
50
|
39.66 ± 2.08*
|
28.54 ± 0.56*
|
1.96 ± 0.07*
|
77.67 ± 1.53*
|
| |
100
|
30.85 ± 1.53*
|
15.51 ± 1.12*
|
1.68 ± 0.02*
|
51.01 ± 2.01*
|
- *P < 0.05 (significantly different from the negative control)
